Cargando…

Hepatic expression of multidrug resistance protein 2 in biliary atresia

BACKGROUND: Biliary atresia (BA) is an idiopathic inflammatory obliterative cholangiopathy of neonates, leading to progressive biliary cirrhosis. Hepatoportoenterostomy (Kasai procedure) can cure jaundice in 30% to 80% of patients. Postoperative clearance of jaundice is one of the most important fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Terui, Keita, Saito, Takeshi, Hishiki, Tomoro, Sato, Yoshiharu, Mitsunaga, Tetsuya, Yoshida, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161838/
https://www.ncbi.nlm.nih.gov/pubmed/21813008
http://dx.doi.org/10.1186/1476-5926-10-6
_version_ 1782210738556764160
author Terui, Keita
Saito, Takeshi
Hishiki, Tomoro
Sato, Yoshiharu
Mitsunaga, Tetsuya
Yoshida, Hideo
author_facet Terui, Keita
Saito, Takeshi
Hishiki, Tomoro
Sato, Yoshiharu
Mitsunaga, Tetsuya
Yoshida, Hideo
author_sort Terui, Keita
collection PubMed
description BACKGROUND: Biliary atresia (BA) is an idiopathic inflammatory obliterative cholangiopathy of neonates, leading to progressive biliary cirrhosis. Hepatoportoenterostomy (Kasai procedure) can cure jaundice in 30% to 80% of patients. Postoperative clearance of jaundice is one of the most important factors influencing long-term outcomes of BA patients. Multidrug resistance protein 2 (MRP2) is one of the canalicular export pumps located in hepatocytes; it exports organic anions and their conjugates (e.g., bilirubin) into bile canaliculus. Although MRP2 is an essential transporter for the excretion of bilirubin, its role in the clinical course of BA patients is unclear. The present study investigated the relationship between hepatic MRP2 expression and clinical course in BA patients, with particular emphasis in curing jaundice after hepatoportoenterostomy. RESULTS: No significant differences in hepatic MRP2 expression level were observed between BA and controls groups. There was no correlation between MRP2 expression and age at time of surgery in BA and control groups. In BA patients, MRP2 expression level in the jaundice and jaundice-free group did not differ significantly (2.0 × 10(-4 )vs 3.1 × 10(-4), p = 0.094). Although the serum level of total bilirubin just before surgery did not correlate with MRP2 expression level (rs = 0.031, p = 0.914), the serum level of total bilirubin measured at 2 weeks (rs = -0.569, p = 0.034) and 4 weeks after surgery (rs = -0.620, p = 0.018) were significantly correlated with MRP2 expression level. Furthermore, MRP2 expression level was inversely correlated with ratio of change in serum total bilirubin level over 4 weeks (rs = -0.676, p = 0.008), which represents the serum bilirubin level measured at 4 weeks after surgery divided by value just before surgery. There was no correlation between expression level of MRP2 and nuclear receptors, such as retinoid × receptor α, farnesoid × receptor, pregnane × receptor, or constitutive androstane receptor. CONCLUSIONS: Hepatic MRP2 expression level was associated with postoperative clearance of jaundice in BA patients, at least within 1 month after hepatoportoenterostomy. This finding suggests that not only morphological appearance of the liver tissue but also the biological status of hepatocytes is important for BA pathophysiology.
format Online
Article
Text
id pubmed-3161838
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31618382011-08-26 Hepatic expression of multidrug resistance protein 2 in biliary atresia Terui, Keita Saito, Takeshi Hishiki, Tomoro Sato, Yoshiharu Mitsunaga, Tetsuya Yoshida, Hideo Comp Hepatol Research BACKGROUND: Biliary atresia (BA) is an idiopathic inflammatory obliterative cholangiopathy of neonates, leading to progressive biliary cirrhosis. Hepatoportoenterostomy (Kasai procedure) can cure jaundice in 30% to 80% of patients. Postoperative clearance of jaundice is one of the most important factors influencing long-term outcomes of BA patients. Multidrug resistance protein 2 (MRP2) is one of the canalicular export pumps located in hepatocytes; it exports organic anions and their conjugates (e.g., bilirubin) into bile canaliculus. Although MRP2 is an essential transporter for the excretion of bilirubin, its role in the clinical course of BA patients is unclear. The present study investigated the relationship between hepatic MRP2 expression and clinical course in BA patients, with particular emphasis in curing jaundice after hepatoportoenterostomy. RESULTS: No significant differences in hepatic MRP2 expression level were observed between BA and controls groups. There was no correlation between MRP2 expression and age at time of surgery in BA and control groups. In BA patients, MRP2 expression level in the jaundice and jaundice-free group did not differ significantly (2.0 × 10(-4 )vs 3.1 × 10(-4), p = 0.094). Although the serum level of total bilirubin just before surgery did not correlate with MRP2 expression level (rs = 0.031, p = 0.914), the serum level of total bilirubin measured at 2 weeks (rs = -0.569, p = 0.034) and 4 weeks after surgery (rs = -0.620, p = 0.018) were significantly correlated with MRP2 expression level. Furthermore, MRP2 expression level was inversely correlated with ratio of change in serum total bilirubin level over 4 weeks (rs = -0.676, p = 0.008), which represents the serum bilirubin level measured at 4 weeks after surgery divided by value just before surgery. There was no correlation between expression level of MRP2 and nuclear receptors, such as retinoid × receptor α, farnesoid × receptor, pregnane × receptor, or constitutive androstane receptor. CONCLUSIONS: Hepatic MRP2 expression level was associated with postoperative clearance of jaundice in BA patients, at least within 1 month after hepatoportoenterostomy. This finding suggests that not only morphological appearance of the liver tissue but also the biological status of hepatocytes is important for BA pathophysiology. BioMed Central 2011-08-03 /pmc/articles/PMC3161838/ /pubmed/21813008 http://dx.doi.org/10.1186/1476-5926-10-6 Text en Copyright ©2011 Terui et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Terui, Keita
Saito, Takeshi
Hishiki, Tomoro
Sato, Yoshiharu
Mitsunaga, Tetsuya
Yoshida, Hideo
Hepatic expression of multidrug resistance protein 2 in biliary atresia
title Hepatic expression of multidrug resistance protein 2 in biliary atresia
title_full Hepatic expression of multidrug resistance protein 2 in biliary atresia
title_fullStr Hepatic expression of multidrug resistance protein 2 in biliary atresia
title_full_unstemmed Hepatic expression of multidrug resistance protein 2 in biliary atresia
title_short Hepatic expression of multidrug resistance protein 2 in biliary atresia
title_sort hepatic expression of multidrug resistance protein 2 in biliary atresia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161838/
https://www.ncbi.nlm.nih.gov/pubmed/21813008
http://dx.doi.org/10.1186/1476-5926-10-6
work_keys_str_mv AT teruikeita hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia
AT saitotakeshi hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia
AT hishikitomoro hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia
AT satoyoshiharu hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia
AT mitsunagatetsuya hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia
AT yoshidahideo hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia